(Q34532600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Pharmacogenetics of the proton pump inhibitors: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Elaine Chong

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 April 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

460-471

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12680476%20AND%20SRC:MED&resulttype=core&format=json

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Review article: the pharmacokinetics of rabeprazole in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Drug interactions with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

The CYP2C19 enzyme polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Pharmacokinetic considerations in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Proton pump inhibitors and their drug interactions: an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Pharmacogenetics: the therapeutic drug monitoring of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.460.32128